Acceleron Pharma Inc

Acceleron Pharma — ASH 2018 MEDALIST & BELIEVE Phase 3 Trial Presentation call

41 slides from Acceleron Pharma's conference presentation, Dec 3, 2018

  1. Slide 1: ASH 2018 MEDALIST & BELIEVE Phase 3 Trial Presentation Highlights

    Exhibit 99.3 ASH 2018 MEDALIST & BELIEVE Phase 3 Trial Presentation Highlights December 3, 2018

  2. Slide 2: ASH 2018 Call Agenda

    ASH 2018 Call Agenda Introduction Welcome/Agenda – Todd James, IRC Luspatercept and ASH 2018 Overview – Habib Dable MEDALIST Phase 3 Trial Results Phase 3 Results Alan F. List, M.D. – Moffitt Cancer Center BELIEVE Phase 3 Trial Results Maria Domenica Cappellini, M.D. – University of Milan Summary/Cl

  3. Slide 3: Acceleron Forward-Looking Statements

    Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company

  4. Slide 4: Habib Dable, Chief Executive Officer

    Habib Dable Chief Executive Officer

  5. Slide 5: Building a Platform Treatment for Anemia with Luspatercept

    Building a Platform Treatment for Anemia with Luspatercept Phase 1 Phase 2 Phase 3 Hematology Luspatercept MEDALIST Phase 3 Trial Myelodysplastic Syndromes (MDS) COMMANDS Phase 3 Trial BELIEVE Phase 3 Trial Beta-Thalassemia BEYOND Phase 2 Trial MF Phase 2 Myelofibrosis (MF) Phase 2 Base/Extension MD

  6. Slide 6: MEDALIST and BELIEVE Phase 3 Trial Presentations

    MEDALIST and BELIEVE Phase 3 Trial Presentations ƒ Session: Plenary Scientific Session ƒ Session: Thalassemia Globin Gene Regulation: Clinical ƒ Date: Sunday, December 2nd ƒ Date: Saturday, December 1st 6

  7. Slide 7: Alan F. List, M.D.

    Alan F. List, M.D. President and CEO of Moffitt Cancer Center, Senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program; Professor of Internal Medicine and Oncology at the University of South Florida Morsani College of Medicine 7

  8. Slide 8: The MEDALIST Trial: Results of a Phase 3 Study of Luspatercept

    The MEDALIST Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) Associated Anemia With Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Pierre

  9. Slide 9: MEDALIST Trial Background and Rationale

    MEDALIST Trial Background and Rationale • Patients with lower-risk (LR)a transfusion-dependent MDS have a poorer prognosis, with greater risk of progression to AML and inferior overall survival compared with patients with transfusion-independent MDS • RBC transfusion-dependent LR, non-del(5q) MDS pa

  10. Slide 10: MEDALIST Trial Luspatercept

    MEDALIST Trial Luspatercept • Luspatercept is a first-in-class erythroid maturation agent that neutralizes select TGF-β superfamily ligands to inhibit aberrant Smad2/3 signaling and enhance late-stage erythropoiesis in MDS models1 • In a phase 2 study in LR, non-del(5q) MDS, luspatercept yielded a h

  11. Slide 11: MEDALIST Trial Study Design

    MEDALIST Trial Study Design – A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Patient Population Luspatercept 1.0 mg/kg (s.c.) every 21 days • MDS-RS (WHO): ≥ 15% RS or ≥ 5% with SF3B1 n = 153 mutation Randomize Dose titrated up to a maximum of 1.75 mg/kg • < 5% blasts in bone marrow 2

  12. Slide 12: MEDALIST Trial Study Endpoints

    MEDALIST Trial Study Endpoints Primary endpoint: • Red blood cell transfusion independence ≥ 8 weeks (weeks 1–24) Key secondary endpoints: • Red blood cell transfusion independence ≥ 12 weeks (weeks 1–24) • Red blood cell transfusion independence ≥ 12 weeks (weeks 1–48) Additional secondary endpoint

  13. Slide 13: MEDALIST Trial Demographics and Baseline Disease Characteristics

    MEDALIST Trial Demographics and Baseline Disease Characteristics Luspatercept Placebo Characteristic (n = 153) (n = 76) Age, median (range), years 71 (40–95) 72 (26–91) Male, n (%) 94 (61.4) 50 (65.8) Time since original MDS diagnosis, median (range), months 44.0 (3–421) 36.1 (4–193) WHO classificat

  14. Slide 14: MEDALIST Primary Endpoint: RBC Transfusion Independence ≥ 8 Weeks

    MEDALIST Trial Primary Endpoint: Red Blood Cell Transfusion Independence ≥ 8 Weeks Luspatercept Placebo RBC-TI ≥ 8 weeks (n = 153) (n = 76) Weeks 1–24, n (%) 58 (37.9) 10 (13.2) 95% CI 30.2–46.1 6.5–22.9 P valuea < 0.0001 a Cochran–Mantel–Haenszel test stratified for average baseline RBC transfusion

  15. Slide 15: MEDALIST Primary Endpoint: Subgroup Analysis

    MEDALIST Trial Primary Endpoint: Subgroup Analysis Luspatercept, n (%) Placebo, n (%) OR (95% CI) P Value Overall 58/153 (37.9) 10/76 (13.2) 5.06 (2.28–11.3) < 0.0001 Average baseline RBC transfusion requirement ≥ 6 units/8 weeks 6/66 (9.1) 1/33 (3.0) 3.20 (0.37–27.7) 0.2699 < 6 units/8 weeks 52/87

  16. Slide 16: MEDALIST Duration of RBC-TI Response in Responders

    MEDALIST Trial Duration of RBC-TI Response in Primary Endpoint Responders 1.0 Median duration (weeks) (95% CI): 30.6 (20.6–40.6) vs 13.6 (9.1–54.9) 0.9 Luspatercept 0.8 Placebo 0.7 Censored 0.6 0.5 RBC-TI 0.4 0.3 0.2 0.1 Probability Probability of Maintaining 0 0 10 20 30 40 50 60 70 80 90 100 110 1

  17. Slide 17: MEDALIST Secondary Endpoint: Erythroid Response (HI-E)

    MEDALIST Trial Secondary Endpoint: Erythroid Response (HI-E) Luspatercept Placebo (n = 153) (n = 76) Achieved HI-Ea (weeks 1–24), n (%) 81 (52.9) 9 (11.8) Reduction of ≥ 4 RBC units/8 weeks (baseline transfusion burden ≥ 4 units/8 weeks) 52/107 (48.6) 8/56 (14.3) Hb increase of ≥ 1.5 g/dL (baseline

  18. Slide 18: MEDALIST Change in Hemoglobin Concentration

    MEDALIST Trial Change3 in Hemoglobin Concentration Responder receiving luspatercept Non-responder receiving luspatercept Placebo 2 1 SE) FromBaseline (g/dL) ± 0 P <0.0001 -1 11/5/2018Baseline 1 211/26/20183 12/17/20186 1/7/2019912 1/28/201913 2/18/201915 3/11/2019 18 4/1/2019 21 4/22/201924 Hb MeanC

  19. Slide 19: MEDALIST Trial Safety Summary

    MEDALIST Trial Safety Summary Luspatercept Placebo (n = 153) (n = 76) Patients with ≥ 1 TEAE, n (%) 150 (98.0) 70 (92.1) Patients with ≥ 1 serious TEAE 48 (31.4) 23 (30.3) Patients with ≥ 1 Grade 3 or 4 TEAE 65 (42.5) 34 (44.7) Patients with TEAEs leading to deatha 5 (3.3) 4 (5.3) Patients with ≥ 1

  20. Slide 20: MEDALIST Trial Conclusions

    MEDALIST Trial Conclusions • In lower-risk, RS-positive MDS, treatment with luspatercept resulted in a significantly higher percentage of patients who achieved RBC-TI, major RBC transfusion reduction, or hemoglobin increase, compared with placebo • Erythroid responses are durable, with approximately

  21. Slide 21: Maria Domenica Cappellini, M.D.

    Maria Domenica Cappellini, M.D. Chief of the Internal Medicine Unit, Professor of Internal Medicine, University of Milan; Chief of the Rare Disease Centre at the Policlinico Hospital IRCCS Foundation Ca’ Granda, Milan, Italy 21

  22. Slide 22: The BELIEVE Trial: Results of a Phase 3 Study of Luspatercept

    The BELIEVE Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions Maria Domenica Cappellini, Vip Viprakasit, Ali Taher, Pencho Georgiev, Kevin H.M. Kuo, Thomas Coates, E

  23. Slide 23: BELIEVE Trial Background

    BELIEVE Trial BACKGROUND • β-thalassemia is a hereditary hemoglobinopathy due to a globin chain synthesis production defect, leading to ineffective erythropoiesis and anemia1–3 • Currently the standard of care for management of β-thalassemia is life-long red blood cell transfusions and iron chelatio

  24. Slide 24: BELIEVE Trial Study Design

    BELIEVE Trial A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY β-thalassemiaa patients Current study ≥ 18 years, statusc requiring regular Luspaterceptb RBC transfusions 1 mg/kg s.c. every 21 days + BSC (defined as: (n = 224) 6–20 RBC units in the Open- Post- 24 weeks prior to 2:1 May b

  25. Slide 25: BELIEVE Primary Endpoint Met: Rate of Erythroid Response

    BELIEVE Trial PRIMARY ENDPOINT MET: RATE OF ERYTHROID RESPONSE A significantly greater proportion of luspatercept-treated patients achieved a ≥ 33% reduction from baseline in transfusion burden during weeks 13 to 24 Luspatercept 30 Placebo P < 0.0001 (OR 5.79, 95% CI 2.24–14.97) 25 20 15 21.4% (n =

  26. Slide 26: BELIEVE Primary Endpoint: Subgroup Analysis Favors Luspatercept

    BELIEVE Trial PRIMARY ENDPOINT: SUBGROUP ANALYSIS FAVORS LUSPATERCEPT Luspatercept Placebo Sub-groups OR (95% CI) P value n/N (%) n/N (%) Overall 48/224 (21.4) 5/112 (4.5) 5.79 (2.24, 14.97) < 0.0001 Region: North America & Europe 23/100 (23.0) 1/51(2.0) 14.94 (1.95, 114.12) 0.0009 Region: Middle Ea

  27. Slide 27: BELIEVE All Key Secondary Endpoints Met

    BELIEVE Trial ALL KEY SECONDARY ENDPOINTS MET: RATES OF ERYTHROID RESPONSE A significantly greater proportion of luspatercept-treated patients achieved clinically meaningful reductions in transfusion burden of ≥ 33% and ≥ 50% 30 Luspatercept P < 0.0001a 25 Placebo 20 P = 0.0017c 15 P = 0.0303b 10 19

  28. Slide 28: BELIEVE Reduction in Transfusion Burden During Any 12- and 24-Week Interval

    BELIEVE Trial REDUCTION IN TRANSFUSION BURDEN DURING ANY 12- AND 24-WEEK INTERVAL During any 12- or 24-week interval, a significantly greater proportion of luspatercept-treated patients achieved clinically meaningful reductions in transfusion burden of ≥ 33% and ≥ 50% Any 12-week interval Any 24-wee

  29. Slide 29: BELIEVE Additional Endpoints: Iron Parameters

    BELIEVE Trial ADDITIONAL ENDPOINTS: IRON PARAMETERS Luspatercept Placebo LS Mean of 95% CI P Value (n = 224) (n = 112) Difference Mean change from baseline at week 48 Serum ferritin, μg/L (SD) −245 (780) 105 (521) −340 −502, −177 < 0.0001 LIC, mg/g dry weight (SD) 0.10 (5.760) 0.08 (5.229) 0.11 −1.1

  30. Slide 30: BELIEVE Safety Summary

    BELIEVE Trial SAFETY SUMMARY Luspatercept Placebo Treatment-Emergent Adverse Events, n (%) (n = 223a) (n = 109a) Patients with at least 1 TEAE (any grade) 214 (96.0) 101 (92.7) Patients with at least 1 grade TEAE (grade ≥ 3)b 65 (29.1) 17 (15.6) Patients with at least 1 serious TEAEc 34 (15.2) 6 (5.

  31. Slide 31: BELIEVE TEAEs by Frequency ≥ 10% in Either Arm

    BELIEVE Trial TEAEs BY FREQUENCY ≥ 10% IN EITHER ARM (ALL GRADES) Luspatercept Placebo n (%) (n = 223a) (n = 109a) Back pain 61 (27.4) 32 (29.4) Upper respiratory tract infection 59 (26.5) 36 (33.0) Headache 58 (26.0) 26 (23.9) Bone pain 44 (19.7) 9 (8.3) Arthralgia 43 (19.3) 13 (11.9) Pyrexia 36 (1

  32. Slide 32: BELIEVE Grade 3–4 TEAEs by Frequency ≥ 1%

    BELIEVE Trial GRADE 3–4 TEAEs BY FREQUENCY ≥ 1% IN EITHER ARM Luspatercept Placebo n (%) (n = 223a) (n = 109a) Anemia 7 (3.1) 0 Increased LIC 6 (2.7) 1 (0.9) Hyperuricemia 6 (2.7) 0 Hypertension 4 (1.8) 0 Syncope 4 (1.8) 0 Back pain 3 (1.3) 1 (0.9) Bone pain 3 (1.3) 0 Blood uric acid increased 3 (1.

  33. Slide 33: BELIEVE Trial Conclusions

    BELIEVE Trial CONCLUSIONS • Luspatercept showed a statistically significant improvement in the primary endpoint of ≥ 33% reduction in transfusion burden compared with placebo • Statistical significance was also demonstrated with luspatercept versus placebo for all key secondary endpoints, including

  34. Slide 34: Habib Dable, Chief Executive Officer

    Habib Dable Chief Executive Officer

  35. Slide 35: ASH 2018 Takeaways

    ASH 2018 Takeaways Low-to-Intermediate Risk MDS, RS+ β-Thalassemia, Transfusion-Dependent ƒ Unmet Medical Need: High disease burden with no approved agents for anemia ƒ Positive Results: Luspatercept met all primary and key secondary endpoints ƒ Duration and Safety: Durable responses with an appropr

  36. Slide 36: Additional Luspatercept Trials Underway

    Additional Luspatercept Trials Underway Phase 3 Lower-Risk MDS, First-line ƒ Enrolling up to 350 patients Phase 2 Phase 2 β-Thalassemia, Non-Transfusion- Monotherapy / Combination Therapy Dependent ƒ Enrolling up to 150 patients ƒ Enrolling up to 70 patients 36

  37. Slide 37: A Potential Platform Treatment for Chronic Anemias

    A Potential Platform Treatment for Chronic Anemias Potential US/EU Addressable Patient Population: >120K Second-line MDS (RS+) Beta-Thalassemia (TD) >40K PATIENTS >20K PATIENTS Myelofibrosis First-line MDS Beta-Thalassemia (NTD) >25K PATIENTS >20K PATIENTS >15K PATIENTS Additional anemia indications

  38. Slide 38: Collaborating for Over 10 Years in Hematology

    Collaborating for Over 10 Years in Hematology Worldwide Royalty Program Costs Low- to mid-20% 100% Celgene funded Milestones Co-Promote $185M outstanding North America 38

  39. Slide 39: Upcoming Luspatercept Corporate Priorities

    Upcoming Luspatercept Corporate Priorities HEMATOLOGY ƒ Luspatercept – Regulatory application submissions in US and EU in 1H 2019 – MEDALIST and BELIEVE Phase 3 trial results publication in 2019 – Myelofibrosis Phase 2 trial preliminary topline results in 2H 2019 – BEYOND Phase 2 trial preliminary t

  40. Slide 40: ASH 2018: Q&A Session

    ASH 2018: Q&A Session Habib Dable Chief Executive Officer Alan F. List, M.D. Moffitt Cancer Center Nica Cappellini, M.D. University of Milan Robert Zeldin, M.D. Chief Medical Officer John Quisel, Ph.D., J.D. Chief Business Officer Sujay Kango Chief Commercial Officer Todd James, IRC VP, Investor Rel

  41. Slide 41: Thank You

    THANK YOU www.acceleronpharma.com NASDAQ: XLRN

Acceleron Pharma — ASH 2018 MEDALIST & BELIEVE Phase 3 Trial Presentation call on 6ix